Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Generally healthy, postmenopausal women; at least 12 months of spontaneous amenorrhea or at least 6 months of spontaneous amenorrhea with serum FSH levels \> 40 mIU/mL or at least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy).~2. Minimum of 7 moderate to severe hot flushes per day or 50 moderate to severe hot flushes per week at screening:~   * Moderate hot flush: warm sensation with sweating, does not disrupt activity.~  * Severe hot flush: hot sensation with sweating, disrupts activity.~3. Subjects must have body mass index (BMI) less than or equal to 40 using the nomograph for BMI.~Exclusion Criteria:~1. Hypersensitivity to venlafaxine (Effexor or Effexor XR).~2. Use of oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks prior to screening; use of transdermal hormone products within 8 weeks prior to screening; use of vaginal hormone products (rings, creams, gels) within 4 weeks prior to screening; use of intrauterine progestins within 8 weeks prior to screening; use of progestin implants or estrogen injectables within 3 months prior to screening; use of estrogen pellet or progestin injectables within 6 months prior to screening.~3. History of a seizure disorder other than a single childhood febrile seizure.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).